Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Chimerix Inc (CMRX)

Chimerix Inc (CMRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 189,506
  • Shares Outstanding, K 61,930
  • Annual Sales, $ 12,520 K
  • Annual Income, $ -112,580 K
  • 60-Month Beta 1.95
  • Price/Sales 15.34
  • Price/Cash Flow N/A
  • Price/Book 1.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.19
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +51.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +9.29%
on 06/15/20
3.33 -8.18%
on 06/23/20
-0.04 (-1.29%)
since 06/10/20
3-Month
1.37 +123.36%
on 04/23/20
3.88 -21.24%
on 05/14/20
+1.54 (+101.98%)
since 04/09/20
52-Week
1.19 +157.14%
on 03/19/20
3.88 -21.24%
on 05/14/20
-0.70 (-18.62%)
since 07/10/19

Most Recent Stories

More News
ADMA Biologics Announces Martha J. Demski Elected to Board of Directors

ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced...

CMRX : 3.06 (-1.29%)
ADMA : 2.83 (-1.39%)
Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Allen Melemed, M.D.,...

LLY : 163.36 (-1.86%)
CMRX : 3.06 (-1.29%)
Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Company management, including Mike...

CMRX : 3.06 (-1.29%)
Chimerix to Present at Jefferies Virtual Healthcare Conference

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer,...

CMRX : 3.06 (-1.29%)
AskBio Announces Appointment of Tim Trost as Chief Financial Officer

Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Trost as Chief Financial Officer. Mr. Trost...

ARGS : 0.1000 (unch)
CMRX : 3.06 (-1.29%)
Chimerix (CMRX) Reports Q1 Loss, Lags Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CMRX : 3.06 (-1.29%)
Chimerix: 1Q Earnings Snapshot

DURHAM, N.C. (AP) _ Chimerix Inc. (CMRX) on Thursday reported a loss of $10.4 million in its first quarter.

CMRX : 3.06 (-1.29%)
Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the first quarter...

CMRX : 3.06 (-1.29%)
Thinking about buying stock in Centennial Resource Development, Chimerix, TherapeuticsMD, Pennsylvania Real Estate, or American Airlines?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDEV, CMRX, TXMD, PEI, and AAL.

AAL : 11.94 (+6.80%)
CDEV : 0.8272 (+8.02%)
CMRX : 3.06 (-1.29%)
PEI : 1.2800 (+4.07%)
SmarTrend Watching for Potential Pullback in Shares of Chimerix Inc After 59.26% Gain

Chimerix Inc (NASDAQ:CMRX) traded in a range yesterday that spanned from a low of $1.82 to a high of $2.62. Yesterday, the shares gained 59.3%, which took the trading range above the 3-day high of $1.54...

CMRX : 3.06 (-1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CMRX with:

Business Summary

Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical...

See More

Key Turning Points

2nd Resistance Point 3.19
1st Resistance Point 3.13
Last Price 3.06
1st Support Level 3.02
2nd Support Level 2.98

See More

52-Week High 3.88
Last Price 3.06
Fibonacci 61.8% 2.86
Fibonacci 50% 2.54
Fibonacci 38.2% 2.22
52-Week Low 1.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar